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Purpose
After reviewing some adverse events, such as cardiovas-
cular disease, regarding the use of ephedra-containing
dietary supplements, the Food and Drug Administration
banned the sale of ephedra products on April 12, 2004.
However, according to standard prescriptions recom-
mended by the Committee on Chinese Medicine and
Pharmacy in Taiwan, ephedra is still a popular ingredient
of many Chinese herbal formulas. This paper examined
the association between prescribed ephedra-containing
Chinese herbal products (CHP) and cardiovascular dis-
ease by using the population-based database in Taiwan.
Methods
All patients newly diagnosed with cardiovascular disease
(CVD) from 2006 to 2007 as case subjects, and a random
sample of the entire insured population from 1997 to
2007 excluding patients with CVD, including myocardial
infarction, stroke, arrhythmias, or cardiac sudden death,
as control subjects, were selected from the National
Health Insurance reimbursement database. Subjects with
incomplete data or any hyperlipidemia-related diagnosis
were also excluded. For the association between pre-
scribed ephedra-containing CHP and the occurrence of
CVD, we used multivariable logistic regression models to
estimate odds ratios and 95% confidence intervals. Mod-
els were adjusted for age, sex, residence, prescription of
acetazolamide and/or labetalol, and cumulative doses of
prescribed ephedra-containing CHP.
Results
There were 1,120 case subjects and 41,409 control sub-
jects in the final analysis. There was a significant reduc-
tion of CVD development for consuming ephedra-
related CHP (OR=0.183, p<0.001). Only three items
(Xiao Xu Ming Shang OR=2.212, p<0.001; Gui Qi Shao
Yao Zhi Mu Shang OR=1.701, p<0.001; She Gan Ma
Huang Shang OR=1.441, p=0.006) out of a total of 24
ephedra-related CHP were associated with the risk of
CVD development. No statistically linear dose-response
relationship was observed with the prescribed dose of
ephedra.
Conclusion
Consumption of ephedra-containing CHP does not
increase the occurrence of CVD.
Author details
1China Medical University, Taichung, Taiwan. 2Department of Information
Management, National Formosa University, Yunlin, Taiwan. 3Department of
Chinese Medicine, Changhua Christian Hospital, Changhua, Taiwan.
Published: 12 June 2012
doi:10.1186/1472-6882-12-S1-P283
Cite this article as: Lin et al.: P04.13. Population-based case-control
study of Chinese herbal products containing ephedra and
cardiovascular disease risk. BMC Complementary and Alternative Medicine
2012 12(Suppl 1):P283.
1China Medical University, Taichung, Taiwan
Full list of author information is available at the end of the article
Lin et al. BMC Complementary and Alternative Medicine 2012, 12(Suppl 1):P283
http://www.biomedcentral.com/1472-6882/12/S1/P283
© 2012 Lin et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
